$AUTL
Autolus Therapeutics PLC Stock $autl

$autl Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 20-F Financial Statement

#000173046323000016 Filed on March 07, 2023

Income Statement

Concept	2022 Q4	2022	2021 Q4
Revenue	$3.825M	$6.360M	$180.0K
YoY Change	2025.0%	172.96%	-55.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.412M	$36.67M	$7.591M
YoY Change	-2.36%	-3.5%	-15.75%
% of Gross Profit
Research & Development	$32.19M	$142.0M	$39.64M
YoY Change	-18.79%	10.37%	2.34%
% of Gross Profit
Depreciation & Amortization	$1.649M	$7.422M	$2.104M
YoY Change	-21.63%	-12.25%	26.75%
% of Gross Profit
Operating Expenses	$39.60M	$142.0M	$47.23M
YoY Change	-16.15%	-14.8%	-1.06%
Operating Profit		-$168.0M
YoY Change		1.85%
Interest Expense	-$231.0K	$8.905M	-$1.056M
YoY Change	-78.13%	-383.33%	-2740.0%
% of Operating Profit
Other Income/Expense, Net	$4.452M	-$5.159M	$14.00K
YoY Change	31700.0%	-339.4%	-101.22%
Pretax Income	-$32.07M	-$173.2M	-$48.09M
YoY Change	-33.32%	4.35%	-0.72%
Income Tax	-$5.116M	-$24.37M	-$6.426M
% Of Pretax Income
Net Earnings	-$26.95M	-$148.8M	-$41.67M
YoY Change	-35.32%	4.75%	-2.79%
Net Earnings / Revenue	-704.6%	-2340.24%	-23147.78%
Basic Earnings Per Share		-$1.57
Diluted Earnings Per Share	-$0.25	-$1.57	-$508.0K
COMMON SHARES
Basic Shares Outstanding	173.1M shares	94.99M shares
Diluted Shares Outstanding		94.99M shares

Balance Sheet

Concept	2022 Q4	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$382.4M	$382.4M	$310.3M
YoY Change	23.23%	23.23%	102.44%
Cash & Equivalents	$382.4M		$310.3M
Short-Term Investments
Other Short-Term Assets	$203.0K	$14.36M	$10.36M
YoY Change	-98.04%	38.55%	-25.97%
Inventory
Prepaid Expenses	$12.34M		$8.713M
Receivables	$121.0K	$121.0K	$0.00
Other Receivables	$1.435M	$28.86M	$271.0K
Total Short-Term Assets	$425.8M	$425.8M	$347.0M
YoY Change	22.72%	22.72%	76.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$35.21M	$58.42M	$52.32M
YoY Change	-32.7%	11.67%	-41.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.084M	$6.084M	$6.227M
YoY Change	-2.3%	-2.3%	-15.85%
Total Long-Term Assets	$64.50M	$64.50M	$58.61M
YoY Change	10.06%	10.06%	-39.7%
TOTAL ASSETS
Total Short-Term Assets	$425.8M	$425.8M	$347.0M
Total Long-Term Assets	$64.50M	$64.50M	$58.61M
Total Assets	$490.3M	$490.3M	$405.6M
YoY Change	20.89%	20.89%	37.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$531.0K	$531.0K	$431.0K
YoY Change	23.2%	23.2%	-81.26%
Accrued Expenses	$40.80M	$45.44M	$27.97M
YoY Change	45.86%	62.47%	-9.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$46.37M	$46.37M	$28.55M
YoY Change	62.4%	62.4%	-15.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$116.0K	$145.2M	$63.69M
YoY Change	-99.82%	128.04%	25.87%
Total Long-Term Liabilities	$116.0K	$145.2M	$63.69M
YoY Change	-99.82%	128.04%	25.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$46.37M	$46.37M	$28.55M
Total Long-Term Liabilities	$116.0K	$145.2M	$63.69M
Total Liabilities	$191.6M	$191.6M	$92.24M
YoY Change	107.72%	107.72%	9.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$670.2M		-$521.3M
YoY Change	28.56%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$298.7M	$298.7M	$313.3M
YoY Change
Total Liabilities & Shareholders Equity	$490.3M	$490.3M	$405.6M
YoY Change	20.89%	20.89%	37.85%

Cashflow Statement

Concept	2022 Q4	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	-$26.95M	-$148.8M	-$41.67M
YoY Change	-35.32%	4.75%	-2.79%
Depreciation, Depletion And Amortization	$1.649M	$7.422M	$2.104M
YoY Change	-21.63%	-12.25%	26.75%
Cash From Operating Activities	-$14.57M	-$112.3M	-$9.158M
YoY Change	59.05%	-4.71%	-66.97%
INVESTING ACTIVITIES
Capital Expenditures	$633.0K	$10.84M	-$1.585M
YoY Change	-139.94%	-222.4%	-71.02%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$633.0K	-$10.84M	-$1.585M
YoY Change	-60.06%	22.4%	-71.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$163.9M	$109.4M
YoY Change		-33.4%	27244.25%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	223.5M	$223.6M	147.4M
YoY Change	51.62%	-21.28%	36753.75%
NET CHANGE
Cash From Operating Activities	-14.57M	-$112.3M	-9.158M
Cash From Investing Activities	-633.0K	-$10.84M	-1.585M
Cash From Financing Activities	223.5M	$223.6M	147.4M
Net Change In Cash	208.3M	$72.09M	136.7M
YoY Change	52.42%	-54.19%	-516.68%
FREE CASH FLOW
Cash From Operating Activities	-$14.57M	-$112.3M	-$9.158M
Capital Expenditures	$633.0K	$10.84M	-$1.585M
Free Cash Flow	-$15.20M	-$123.1M	-$7.573M
YoY Change	100.7%	12.98%	-65.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001730463
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q4	autl	Deduction Of Royalties Payable DeductionOfRoyaltiesPayable	0.5
CY2022	dei	Document Type DocumentType	20-F
CY2022	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38547
CY2022	dei	Entity Registrant Name EntityRegistrantName	Autolus Therapeutics plc
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	The Mediaworks
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	191 Wood Lane
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	London
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	W12 7FP
CY2022	dei	Entity Address Country EntityAddressCountry	GB
CY2022	dei	Security12b Title Security12bTitle	American Depository Shares, each representing one ordinary share, nominal value $0.000042 per share
CY2022	dei	Trading Symbol TradingSymbol	AUTL
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	173074510	shares
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Firm AuditorFirmId	1438
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Reading, United Kingdom
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	382436000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	310338000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	325000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	338000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	43010000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	36276000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	425771000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	346952000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35209000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33541000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	2176000	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	2362000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23210000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18775000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1832000	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2039000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2076000	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1826000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	65000	usd
CY2022Q4	us-gaap	Assets Assets	490274000	usd
CY2021Q4	us-gaap	Assets Assets	405560000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	531000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	431000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	40797000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23667000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5038000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4453000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46366000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28551000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19218000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16545000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	125900000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	47016000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	116000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	128000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	191600000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	92240000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1007625000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	843108000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-38898000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8570000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-670179000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-521340000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	298674000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	313320000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	490274000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	405560000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	141992000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	134789000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	134888000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31899000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31865000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34972000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-515000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-676000	usd
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-168046000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-165000000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-168145000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1708000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	262000	usd
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	536000	usd
CY2022	us-gaap	Interest Expense InterestExpense	8905000	usd
CY2021	us-gaap	Interest Expense InterestExpense	1105000	usd
CY2020	us-gaap	Interest Expense InterestExpense	0	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2038000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-145000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1352000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5159000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-988000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1888000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-173205000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-165988000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-166257000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-24366000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-23892000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-24163000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-148839000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-142096000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-142094000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-30328000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2709000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2830000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-179167000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-144805000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-139264000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.57
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.57
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.97
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.97
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.76
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.76
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94993400	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94993400	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72084078	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72084078	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51558075	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51558075	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	254839000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	73953000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20021000	usd
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	483000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2830000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-142094000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	210032000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	228161000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9937000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	127000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	9868000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2709000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-142096000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	313320000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	152390000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12014000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	117000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-30328000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-148839000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	298674000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-148839000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-142096000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-142094000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7422000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8458000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5658000	usd
CY2022	autl	Gain Loss On Disposition Of Property Plant Equipment And Intangible Assets GainLossOnDispositionOfPropertyPlantEquipmentAndIntangibleAssets	-515000	usd
CY2021	autl	Gain Loss On Disposition Of Property Plant Equipment And Intangible Assets GainLossOnDispositionOfPropertyPlantEquipmentAndIntangibleAssets	-672000	usd
CY2020	autl	Gain Loss On Disposition Of Property Plant Equipment And Intangible Assets GainLossOnDispositionOfPropertyPlantEquipmentAndIntangibleAssets	0	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	12014000	usd
CY2021	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	9937000	usd
CY2020	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	20107000	usd
CY2022	autl	Non Cash Interest Expense And Cumulative Catch Up Adjustment NonCashInterestExpenseAndCumulativeCatchUpAdjustment	8884000	usd
CY2021	autl	Non Cash Interest Expense And Cumulative Catch Up Adjustment NonCashInterestExpenseAndCumulativeCatchUpAdjustment	1093000	usd
CY2020	autl	Non Cash Interest Expense And Cumulative Catch Up Adjustment NonCashInterestExpenseAndCumulativeCatchUpAdjustment	0	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-3996000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	usd
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	usd
CY2022	autl	Gain Loss On Incentive And Reassessment GainLossOnIncentiveAndReassessment	0	usd
CY2021	autl	Gain Loss On Incentive And Reassessment GainLossOnIncentiveAndReassessment	-9000	usd
CY2020	autl	Gain Loss On Incentive And Reassessment GainLossOnIncentiveAndReassessment	1335000	usd
CY2022	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	usd
CY2021	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	usd
CY2020	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	160000	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-268000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-72000	usd
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1344000	usd
CY2022	autl	Increase Decrease In Prepaid Expense And Other Assets Current IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent	10962000	usd
CY2021	autl	Increase Decrease In Prepaid Expense And Other Assets Current IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent	-5574000	usd
CY2020	autl	Increase Decrease In Prepaid Expense And Other Assets Current IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent	2660000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-161000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	11453000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-503000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2637000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	5000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-575000	usd
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	508000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	22000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1816000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1439000	usd
CY2022	autl	Increase Decreasein Accrued Liabilities Lease Liability And Other Liabilities IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities	16007000	usd
CY2021	autl	Increase Decreasein Accrued Liabilities Lease Liability And Other Liabilities IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities	-2021000	usd
CY2020	autl	Increase Decreasein Accrued Liabilities Lease Liability And Other Liabilities IncreaseDecreaseinAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities	5608000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1255000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1323000	usd
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	168000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-112308000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-117861000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-117758000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10841000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8857000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14681000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10841000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8857000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14681000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	163854000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	245900000	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	79750000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	117000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	125000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	462000	usd
CY2022	autl	Proceeds From Issuance Of Contract With Customer Liability ProceedsFromIssuanceOfContractWithCustomerLiability	-70000000	usd
CY2021	autl	Proceeds From Issuance Of Contract With Customer Liability ProceedsFromIssuanceOfContractWithCustomerLiability	-50000000	usd
CY2020	autl	Proceeds From Issuance Of Contract With Customer Liability ProceedsFromIssuanceOfContractWithCustomerLiability	0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	10361000	usd
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5797000	usd
CY2022	autl	Payment Of Contract With Customer Liability Issuance Costs PaymentOfContractWithCustomerLiabilityIssuanceCosts	0	usd
CY2021	autl	Payment Of Contract With Customer Liability Issuance Costs PaymentOfContractWithCustomerLiabilityIssuanceCosts	509000	usd
CY2020	autl	Payment Of Contract With Customer Liability Issuance Costs PaymentOfContractWithCustomerLiabilityIssuanceCosts	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	223610000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	284063000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	74415000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-28376000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-754000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	679000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	72085000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	156591000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-57345000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	310676000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154085000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	211430000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	382761000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	310676000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154085000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	471000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	364000	usd
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	1841000	usd
CY2022	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	20044000	usd
CY2021	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	25031000	usd
CY2020	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	21620000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-19573000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-24667000	usd
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-19779000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2864000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3712000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2499000	usd
CY2022	autl	Right Of Use Assets Terminated And Obtained In Exchange For Operating Lease Liability Net RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet	0	usd
CY2021	autl	Right Of Use Assets Terminated And Obtained In Exchange For Operating Lease Liability Net RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet	28517000	usd
CY2020	autl	Right Of Use Assets Terminated And Obtained In Exchange For Operating Lease Liability Net RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet	2487000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9785000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	627000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	26956000	usd
CY2022	autl	Capitalized Sharebased Compensation CapitalizedSharebasedCompensation	-6000	usd
CY2021	autl	Capitalized Sharebased Compensation CapitalizedSharebasedCompensation	0	usd
CY2020	autl	Capitalized Sharebased Compensation CapitalizedSharebasedCompensation	-86000	usd
CY2022	autl	Hosting Arrangement Service Contract Implementation Cost Capitalized After Accumulated Amortization Current And Noncurrent HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent	230000	usd
CY2021	autl	Hosting Arrangement Service Contract Implementation Cost Capitalized After Accumulated Amortization Current And Noncurrent HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent	100000	usd
CY2020	autl	Hosting Arrangement Service Contract Implementation Cost Capitalized After Accumulated Amortization Current And Noncurrent HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent	144000	usd
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1103000	usd
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	245000	usd
CY2020	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction		usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	9868000	usd
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2022Q4	us-gaap	Cash Cash	382436000	usd
CY2021Q4	us-gaap	Cash Cash	310338000	usd
CY2020Q4	us-gaap	Cash Cash	153299000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	325000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	338000	usd
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	786000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	382761000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	310676000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154085000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Nature of the Business<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autolus Therapeutics plc and its subsidiaries (collectively "Autolus" or the “Company”) is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using its broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and attack and kill these cells. The Company believes its programmed T cell therapies have the potential to be best-in-class and offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.</span></div><div style="margin-top:13pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from its product sales.</span></div>The Company has funded its operations primarily with proceeds from the sale of equity securities, through public offerings and sales pursuant to the Company's at-the-market facility, government grants, U.K. research and development tax credits and receipts from the U.K. RDEC Scheme, out-licensing arrangements and strategic collaboration and financing agreements. The Company has incurred recurring losses since its inception, including net losses of $148.8 million, $142.1 million and $142.1 million for the years ended December 31, 2022, 2021 and 2020, respectively. As of December 31, 2022 and 2021, the Company had an accumulated deficit of $670.2 million and $521.3 million, respectively. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations. The Company’s inability to raise additional capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-148800000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-142100000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-142100000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-670200000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-521300000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Actual results could differ from those estimates. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, share-based compensation including assessing the probability of meeting performance conditions, income taxes, initial fair value of warrants, and non-cash interest expense on liability related to future royalties and sales milestones.</span> Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	382400000	usd
CY2022Q4	us-gaap	Assets Net AssetsNet	379400000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-148800000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	382400000	usd
CY2021Q4	autl	Lessor Operating Lease Number Of Contracts LessorOperatingLeaseNumberOfContracts	2	contract
CY2021Q4	us-gaap	Proceeds From Deposits From Customers ProceedsFromDepositsFromCustomers	100000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents and restricted cash. The Company places cash and cash equivalents and restricted cash with established financial institutions with strong credit ratings. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.</span></div>
CY2021	autl	Disposal Group Not Discontinued Operation Gain Loss On Disposal Statement Of Income Extensible List Not Disclosed Flag DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag	loss on disposal
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022Q4	us-gaap	Number Of Countries In Which Entity Operates NumberOfCountriesInWhichEntityOperates	3	region
CY2022	autl	Research And Development Tax Credits ResearchAndDevelopmentTaxCredits	100000	usd
CY2021	autl	Research And Development Tax Credits ResearchAndDevelopmentTaxCredits	100000	usd
CY2020	autl	Research And Development Tax Credits ResearchAndDevelopmentTaxCredits	100000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1800000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2300000	usd
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-200000	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	1600000	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	1700000	usd
CY2020	us-gaap	Professional Fees ProfessionalFees	2100000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-30300000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2700000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2800000	usd
CY2022Q4	autl	Number Of Distinct Performance Obligations NumberOfDistinctPerformanceObligations	1	performanceobligation
CY2022Q4	autl	Research And Development Claims Receivable Current ResearchAndDevelopmentClaimsReceivableCurrent	24685000	usd
CY2021Q4	autl	Research And Development Claims Receivable Current ResearchAndDevelopmentClaimsReceivableCurrent	23678000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	121000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12337000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8713000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	2701000	usd
CY2021Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	1849000	usd
CY2022Q4	autl	Lease And Lease Deposit Receivable Current LeaseAndLeaseDepositReceivableCurrent	32000	usd
CY2021Q4	autl	Lease And Lease Deposit Receivable Current LeaseAndLeaseDepositReceivableCurrent	68000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	203000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	240000	usd
CY2022Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	2000	usd
CY2021Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	384000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1435000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	271000	usd
CY2022Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	1494000	usd
CY2021Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	1073000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	43010000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	36276000	usd
CY2021Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	17985611	shares
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	27542000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22716000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35209000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33541000	usd
CY2022	us-gaap	Depreciation Depreciation	7300000	usd
CY2021	us-gaap	Depreciation Depreciation	8600000	usd
CY2020	us-gaap	Depreciation Depreciation	5700000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	65000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	90000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	91000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10181000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8747000	usd
CY2022Q4	autl	Accrued Research And Development Cost Current AccruedResearchAndDevelopmentCostCurrent	26478000	usd
CY2021Q4	autl	Accrued Research And Development Cost Current AccruedResearchAndDevelopmentCostCurrent	11311000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3745000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3449000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	393000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	160000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	40797000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23667000	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.35
CY2022Q4	autl	Number Of Development Payments NumberOfDevelopmentPayments	2	payment
CY2021Q4	autl	Debt Financing Commitment Maximum Amount To Be Received DebtFinancingCommitmentMaximumAmountToBeReceived	150000000	usd
CY2022Q4	autl	Units Of Accounting UnitsOfAccounting	3	unit
CY2022Q4	autl	Units Of Accounting UnitsOfAccounting	3	unit
CY2022Q4	autl	Units Of Accounting UnitsOfAccounting	3	unit
CY2022Q4	autl	Units Of Accounting UnitsOfAccounting	3	unit
CY2022Q4	autl	Number Of Development Payments NumberOfDevelopmentPayments	2	payment
CY2021	autl	Collaborative Agreement Liability Additions CollaborativeAgreementLiabilityAdditions	45923000	usd
CY2022	autl	Collaborative Agreement Liability Additions CollaborativeAgreementLiabilityAdditions	70000000	usd
CY2022	autl	Collaboration Agreement Cumulative Catch Up Adjustment CollaborationAgreementCumulativeCatchUpAdjustment	879000	usd
CY2022Q4	autl	Collaborative Agreements Debt Liability CollaborativeAgreementsDebtLiability	125900000	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.35
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	10000000.0	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022	autl	Warrants Or Rights Outstanding Fair Value Assumptions Risk Free Interest Rate WarrantsOrRightsOutstandingFairValueAssumptionsRiskFreeInterestRate	0.0104
CY2022	autl	Warrants Or Rights Outstanding Fair Value Assumptions Expected Volatility Rate WarrantsOrRightsOutstandingFairValueAssumptionsExpectedVolatilityRate	0.8023
CY2022	autl	Warrant Or Right Outstanding Fair Value Assumption Expected Dividend Rate WarrantOrRightOutstandingFairValueAssumptionExpectedDividendRate	0
CY2018Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	16000000.0	usd
CY2018Q2	autl	Equity Conversion Ratio EquityConversionRatio	3.185
CY2020Q3	autl	Sale Of Stock Authorized Amount SaleOfStockAuthorizedAmount	100000000	usd
CY2020Q3	autl	Commission Percentage Of Gross Sales Price CommissionPercentageOfGrossSalesPrice	0.030
CY2021	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	29600000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5611429	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.19
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M15D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4262000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4155375	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.11
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	196069	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.64
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1798280	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	17.12
CY2021	autl	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue	0	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9937000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20021000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7772455	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.24
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1007000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3792160	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.19
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	162864	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.72
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	193000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1090951	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	14.02
CY2022	autl	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue	1000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10310800	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.90
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M4D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	96000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3836926	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	15.22
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M21D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	96000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10310800	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.90
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y2M4D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	96000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12014000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-148839000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-142096000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-142094000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-148839000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-148839000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-142096000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-142096000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-142094000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-142094000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94993400	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94993400	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72084078	shares
CY2016Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	313971	shares
CY2018Q1	autl	Accrued License Fees Current AccruedLicenseFeesCurrent	350000	gbp
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72084078	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51558075	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51558075	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.57
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.57
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.97
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.97
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.76
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.76
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13979437	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12127411	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6116812	shares
CY2022Q4	autl	Accrued License Fees Current AccruedLicenseFeesCurrent	180000	gbp
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-24400000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-23900000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-24200000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-173205000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-165988000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-166257000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.190
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.190
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.190
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-32909000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-31580000	usd
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-31589000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	25124000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	24023000	usd
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	23076000	usd
CY2022	autl	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Depreciation And Amortization Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingDepreciationAndAmortizationAmount	3071000	usd
CY2021	autl	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Depreciation And Amortization Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingDepreciationAndAmortizationAmount	302000	usd
CY2020	autl	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Depreciation And Amortization Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingDepreciationAndAmortizationAmount	797000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	496000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	233000	usd
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-1088000	usd
CY2022	autl	Effective Income Tax Rate Reconciliation Operating Income Loss Amount EffectiveIncomeTaxRateReconciliationOperatingIncomeLossAmount	-28671000	usd
CY2021	autl	Effective Income Tax Rate Reconciliation Operating Income Loss Amount EffectiveIncomeTaxRateReconciliationOperatingIncomeLossAmount	-28497000	usd
CY2020	autl	Effective Income Tax Rate Reconciliation Operating Income Loss Amount EffectiveIncomeTaxRateReconciliationOperatingIncomeLossAmount	-28672000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Depreciation And Amortization IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization	828000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Depreciation And Amortization IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization	935000	usd
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Depreciation And Amortization IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization	547000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	583000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1727000	usd
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1552000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	18000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	17000	usd
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	22000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-24366000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-23892000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-24163000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-24154000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-23782000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-22819000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-212000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-110000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1344000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.141
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.144
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.145
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	2100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13576000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	10909000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	80203000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	69642000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	4252000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	6779000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	98031000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	87330000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	95955000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	85504000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	2076000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1826000	usd
CY2022	autl	Increase Decrease In Deferred Tax Assets Gross IncreaseDecreaseInDeferredTaxAssetsGross	-300000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	320800000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	96000000.0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	85500000	usd
CY2020Q3	us-gaap	Incentive From Lessor IncentiveFromLessor	1200000	usd
CY2021Q4	us-gaap	Incentive From Lessor IncentiveFromLessor	0	usd
CY2021Q4	us-gaap	Proceeds From Deposits From Customers ProceedsFromDepositsFromCustomers	100000	usd
CY2022Q4	autl	Number Of Clean Rooms NumberOfCleanRooms	3	room
CY2022Q4	autl	Number Of Clean Rooms NumberOfCleanRooms	3	room
CY2022	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	6400000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23210000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18775000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5038000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4453000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19218000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16545000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	24256000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	20998000	usd
CY2022	us-gaap	Lease Cost LeaseCost	5887000	usd
CY2021	us-gaap	Lease Cost LeaseCost	7475000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	4575000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	4619000	usd
CY2022	autl	Right Of Use Asset Obtained In Exchange For New Operating Lease Liability RightOfUseAssetObtainedInExchangeForNewOperatingLeaseLiability	0	usd
CY2021	autl	Right Of Use Asset Obtained In Exchange For New Operating Lease Liability RightOfUseAssetObtainedInExchangeForNewOperatingLeaseLiability	38335000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y4M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0677
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0715
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6492000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4391000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3453000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3176000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3176000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	12573000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	33261000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9005000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	24256000	usd
CY2021Q4	autl	Lessor Operating Lease Number Of Contracts LessorOperatingLeaseNumberOfContracts	2	contract
CY2021Q4	autl	Lessor Operating Lease Number Of Third Parties LessorOperatingLeaseNumberOfThirdParties	2	thirdparty
CY2021Q4	autl	Lessor Operating Lease Number Of Manufacturing Properties LessorOperatingLeaseNumberOfManufacturingProperties	2	contract
CY2021Q4	us-gaap	Proceeds From Deposits From Customers ProceedsFromDepositsFromCustomers	127000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	240000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	49000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	249000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	249000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	249000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	194000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	117000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Thereafter LessorOperatingLeasePaymentsToBeReceivedThereafter	101000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	1159000	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1700000	usd
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1600000	usd
CY2020	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1300000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	usd
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	usd
CY2021Q1	us-gaap	Severance Costs1 SeveranceCosts1	1200000	usd
CY2021Q4	autl	Number Of Directors NumberOfDirectors	1	director
CY2021Q4	autl	Sale Of Stock Consideration Received On Transaction Gross SaleOfStockConsiderationReceivedOnTransactionGross	100000000.0	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.35

Files In Submission

Name	View Source	Status
0001730463-23-000016-index-headers.html	Edgar Link	pending
0001730463-23-000016-index.html	Edgar Link	pending
0001730463-23-000016.txt	Edgar Link	pending
0001730463-23-000016-xbrl.zip	Edgar Link	pending
autl-20221231.htm	Edgar Link	pending
autl-20221231.xsd	Edgar Link	pending
autl-20221231_g1.jpg	Edgar Link	pending
autl-20221231_g2.jpg	Edgar Link	pending
autl-20221231_g3.jpg	Edgar Link	pending
autl-20221231_g4.jpg	Edgar Link	pending
autolus-20xfx31122022ex121.htm	Edgar Link	pending
autolus-20xfx31122022ex122.htm	Edgar Link	pending
autolus-20xfx31122022ex131.htm	Edgar Link	pending
autolus-ex151consentoferns.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
autl-20221231_cal.xml	Edgar Link	unprocessable
autl-20221231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
autl-20221231_pre.xml	Edgar Link	unprocessable
autl-20221231_htm.xml	Edgar Link	completed
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
autl-20221231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AUTL
Autolus Therapeutics PLC Stock $autl

2022 Q4 Form 20-F Financial Statement

#000173046323000016 Filed on March 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUTL Autolus Therapeutics PLC Stock $autl

2022 Q4 Form 20-F Financial Statement

#000173046323000016 Filed on March 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUTL
Autolus Therapeutics PLC Stock $autl